You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 14, 2025

LIQUAMAR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Liquamar patents expire, and when can generic versions of Liquamar launch?

Liquamar is a drug marketed by Organon Usa Inc and is included in one NDA.

The generic ingredient in LIQUAMAR is phenprocoumon. Additional details are available on the phenprocoumon profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LIQUAMAR?
  • What are the global sales for LIQUAMAR?
  • What is Average Wholesale Price for LIQUAMAR?
Summary for LIQUAMAR
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 93
Patent Applications: 3,497
DailyMed Link:LIQUAMAR at DailyMed
Drug patent expirations by year for LIQUAMAR

US Patents and Regulatory Information for LIQUAMAR

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Organon Usa Inc LIQUAMAR phenprocoumon TABLET;ORAL 011228-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 1 of 1 entries

Pharmaceutical Market Dynamics and Financial Trajectory: A Focus on Liquid Formulations

Introduction

The pharmaceutical industry is undergoing significant transformations driven by advancements in technology, changing consumer preferences, and the need for more effective and convenient drug delivery systems. Liquid formulations, including pharmaceutical suspensions and liquid-filled capsules, are gaining prominence due to their versatility and efficacy. This article delves into the market dynamics and financial trajectory of these liquid formulations, with a particular focus on the factors influencing their growth and the financial performance of key players.

Market Dynamics of Pharmaceutical Suspensions

Growing Demand for Targeted Drug Delivery

Pharmaceutical suspensions are experiencing substantial growth, largely driven by the expanding geriatric population. As people age, they are more likely to develop chronic and acute medical conditions that require targeted and localized drug delivery. Suspensions offer an adaptable and easy-to-administer solution, making them a preferred choice for this demographic[1].

Advancements in R&D

Innovative formulations resulting from advancements in research and development (R&D) are another key factor driving the growth of the pharmaceutical suspensions market. These new formulations cater to specific medical needs, enhancing the market's growth potential[1].

End User and Distribution Channel Trends

Hospitals and clinics currently dominate the market in terms of revenue, but home care settings are anticipated to grow at the fastest CAGR during the forecast period. Similarly, while drug stores and retail pharmacies are the leading distribution channels, online providers are expected to grow at the highest CAGR[1].

Market Dynamics of Liquid-Filled Capsules

Rising Prevalence of Chronic Diseases

The liquid-filled capsules market is driven by the increasing prevalence of chronic diseases and a growing aging population. These capsules offer enhanced bioavailability and quicker absorption compared to traditional solid forms, making them highly sought after for various therapeutic applications[3].

Technological Advancements

Technological advancements in capsule manufacturing, such as the development of moisture-resistant materials and improved encapsulation techniques, have enhanced product stability and efficacy. This has contributed significantly to the market's expansion[3].

Consumer Preferences

Consumers are increasingly seeking easy-to-swallow options, particularly for those who have difficulty ingesting tablets or traditional capsules. The convenience and effectiveness of liquid-filled capsules have made them a popular choice[3].

Financial Trajectory of Key Players

Revenue and Cost Analysis

Companies like Liquidia Corporation, which are involved in the promotion and development of liquid formulations, have seen mixed financial results. For instance, Liquidia Corporation reported a revenue of $3.7 million in the second quarter of 2024, down from $4.8 million in the same period in 2023. The cost of revenue increased due to sales force expansion, while research and development expenses decreased significantly[2].

Investment in R&D

Major pharmaceutical companies like Gilead Sciences are investing heavily in R&D to develop novel therapeutics. Gilead's R&D expenses increased to $5.7 billion in 2023, reflecting increased clinical activities across their Oncology and Virology programs[5].

Market Size and Growth Projections

The pharmaceutical suspensions market is projected to reach USD 83.8 billion by 2032, growing at a CAGR of 4.2% during the forecast period. The liquid-filled capsules market is also expected to grow significantly, driven by the increasing demand for innovative delivery systems and personalized medicine[1][3].

Regional Market Analysis

North America and Asia-Pacific

North America currently generates the largest revenue in the pharmaceutical suspensions market, but Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period. Similarly, in the liquid-filled capsules market, North America dominates, but regions like Europe are expected to show significant growth due to increased research and development activities[1][4].

Challenges and Opportunities

High Production Costs

One of the major challenges facing the liquid-filled capsules market is the high production cost associated with manufacturing these capsules. This can limit accessibility for smaller manufacturers and startups[3].

Competition from Alternative Dosage Forms

The market also faces competition from alternative dosage forms such as tablets and powders, which may be perceived as more familiar or cost-effective by consumers[3].

Emerging Trends

Despite these challenges, emerging trends such as the shift toward natural and plant-based formulations, and the growing interest in personalized medicine, present significant opportunities for market growth. Companies are focusing on research and development to create innovative liquid formulations that meet specific health needs[3].

Competitive Strategy

Market Rivals and Competitive Edge

To maintain a competitive edge, companies need to evaluate market rivals and adopt strategies that differentiate them. This includes focusing on innovative product development, targeting specialized market segments, and implementing creative marketing initiatives[3].

Key Market Players

Key players such as Glenmark Pharmaceuticals Limited, AstraZeneca plc, Teva Pharmaceutical Industries Limited, and others are positioning themselves through strategic R&D investments and market expansion. These companies are leveraging advancements in technology and changing consumer preferences to drive their growth[1].

Technological Advancements in Liquid Handling Systems

Automated Liquid Handling Systems

The use of automated liquid handling systems in drug discovery and high-throughput screening is becoming more prevalent. This trend is expected to drive the growth of the liquid handling system market, which is projected to reach USD 7.00 billion by 2033, growing at a CAGR of 4.8% during the forecast period[4].

Impact on Drug Production

Liquid handling systems are extensively used in drug production, cancer research, and clinical diagnostics. The growth in these industries is expected to positively impact the market for liquid handling systems, particularly in regions like North America, which leads in research and development spending[4].

Key Takeaways

  • The pharmaceutical suspensions and liquid-filled capsules markets are driven by the growing geriatric population and advancements in R&D.
  • High production costs and competition from alternative dosage forms are significant challenges.
  • Emerging trends such as personalized medicine and natural formulations present opportunities for growth.
  • Key players are investing heavily in R&D and adopting competitive strategies to maintain market position.
  • Technological advancements in liquid handling systems are crucial for drug discovery and production.

FAQs

What are the primary drivers of the pharmaceutical suspensions market?

The primary drivers include the expanding geriatric population and advancements in R&D leading to innovative formulations.

How is the liquid-filled capsules market expected to grow?

The market is expected to grow significantly driven by the increasing prevalence of chronic diseases, technological advancements, and consumer preferences for easy-to-swallow options.

What are the major challenges facing the liquid-filled capsules market?

High production costs and competition from alternative dosage forms are major challenges.

Which region is expected to grow the fastest in the pharmaceutical suspensions market?

Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

How are technological advancements in liquid handling systems impacting the market?

Automated liquid handling systems are driving growth in drug discovery, high-throughput screening, and clinical diagnostics, particularly in regions like North America.

Sources

  1. Allied Market Research: Pharmaceutical Suspension Market Size, Growth| Forecast- 2032.
  2. Liquidia Corporation: Liquidia Corporation Reports Second Quarter 2024 Financial.
  3. ResearchAndMarkets.com: Liquid Filled Capsule Market Analysis and Forecast, 2024-2034.
  4. Straits Research: Liquid Handling System Market Size, Share, Growth | Outlook 2033.
  5. Gilead Sciences: Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.